Expression of FXYD3 protein in relation to biological and clinicopathological variables in colorectal cancers

Chemotherapy

Volumn 55, Issue 6, 2009, Pages 407-413

  Widegren, Emma ^a   Önnesjö, Sofia ^a   Arbman, Gunnar ^b   Kayed, Hany ^d   Zentgraf, Hanswalter ^e   Kleeff, Jörg ^f   Zhang, Hong ^c   Sun, Xiao Feng ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b VRINNEVI HOSPITAL   (Sweden)

^c UNIVERSITY OF SKÖVDE   (Sweden)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Colorectal cancer; FXYD3; Immunohistochemistry

Indexed keywords

CYCLINE; FXYD3 PROTEIN; LEGUMAIN; PROTEIN P53; RAS PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DUKE STAGE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MCNEMAR TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTESTINAL MUCOSA; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; SURVIVAL RATE;

EID: 70849137093     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000263227     Document Type: Article

References (22)

1. Geering K: FXYD3 proteins: new regulators of Na-K-ATPase. Am J Physiol Renal Physiol 2006; 290: 241-250.
2. Morrison BW, Moorman JR, Kowdley GC, Kobayashi YM, Jones LR, Leder P: Mat-8, a novel phospholemman-like protein expressed in human breast tumors, induces a chloride conductance in Xenopus oocytes. J Biol Chem 1995; 270: 2176-2182.
3. Crambert G, Li C, Claeys D, Geering K: FXYD3 (Mat-8), a new regulator of Na, KATPase. Mol Biol Cell 2005; 16: 2363-2371.
4. Arimochi J, Ohashi-Kobayashi A, Maeda M: Interaction of Mat-8 (FXYD-3) with Na+/ K+-ATPase in colorectal cancer cells. Biol Pharm Bull 2007; 30: 648-654.
5. Kayed H, Kleeff J, Kolb A, Ketterer K, Keleg S, Felix K, Giese T, Penzel R, Zentgraf H, Buchler MW, Korc M, Friess H: FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. Int J Cancer 2006; 118: 43-54.
6. Vaarala MH, Porvari K, Kyllonen A, Vihko P: Differently expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression. Lab Invest 2000; 80: 1259-1268.
7. Grzmil M, Voight S, Thelen P, Hemmerlein B, Helmke K, Burfeind P: Up-regulated expression of the Mat-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells. Int J Oncol 2004; 29: 97-105.
8. Maxwell PJ, Longley DB, Latif T, Boyer J, Allen W, Lynch M, McDermott U, Harkin DP, Allegra CJ, Johnston PG: Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res 2003; 63: 4602-4606.
9. Bibert S, Aebischer D, Desgranges F, Roy S, Schaer D, Kharoubi-Hess S, Horisberger JD, Geering K: A link between FXYD3 (Mat-8)- mediated Na,K-ATPase regulation and differentiation of Caco-2 intestinal epithelial cells. Mol Biol Cell 2009; 20: 1132-1140.
10. Sun XF, Zhang H, Ekberg H, Carstensen JM, Nordenskjold B: Overexpression of ras is an independent prognostic factor in colorectal adenocarcinoma. APMIS 1998; 106: 654-656.
11. Sun XF, Carstensen JM, Zhang H, Arbman G, Nordenskjold B: Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas. Eur J Cancer 1996; 11: 1963-1967.
12. Sun XF, Carstensen JM, Stal O, Zhang H, Arbman G, Nordenskjold B: Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2, p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma. Int J Cancer 1996; 69: 5-8.
13. Murthy R.V, Arbman G, Gao J, Roodman GD, Sun XF: Legumain expression in relation to clinicopathological and biological variables. Clin Cancer Res 2005; 11: 2293-2299.
14. Loftas P, Onnesjo S, Widgren E, Adell G, Kayed H, Kleef J, Zentgraf H, Sun XF: Expression of FXYD-3 is an independent prognostic factor in rectal cancer patients with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2009, E-pub ahead of print.
15. Anderle P, Rakhmanova V, Woodford K, Zerangue N, Sadee W: Messenger RNA expression of transporter and ion channel genes in undifferentiated and differentiated Caco-2 cells compared to human intestines. Pharm Res 2003; 20: 3-15.
16. Skoglund J, Emterling A, Arbman G, Anglard P, Sun XF: Clinicopathological significance of stromelysin-3 expression in colorectal cancer. Oncology 2004; 67: 67-72. (Pubitemid 39370353)
17. Komuro K, Tada M, Tamoto E, Kawakami A, Matsunaga A, Teramoto K, Shindoh G, Takada M, Murakawa K, Kanai M, Kobaya-shi N, Fujiwara Y, Nishimura N, Hamada J, Ishizu A, Ikeda H, Kondo S, Katoh H, Mo-riuchi T, Yoshiki T: Right- and left-sided colorectal cancers display distinct expression profiles and the anatomical stratification allows a high accuracy prediction of lymph node metastasis. J Surg Res 2005; 124: 216-224.
18. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355: 1745-1750.
19. Morrison BW, Leder P: neu and ras initiate murine mammary tumours that share genetic markers generally absent in c-myc and int-2-initiated tumours. Oncogene 1994; 9: 3417-3426.
20. Andreyev HJN, Norman AR, Cunningham D, Oates JR, Clarke PA: Kirsten ras mutations in patients with colorectal cancer: the multicenter 'Rascal' study. J Natl Cancer Inst 1998; 90: 675-683.
21. Morgunkova AA: The p53 gene family: control of cell proliferation and developmental programs. Biochemistry 2005; 70: 955-971.
22. Liu C, Sun C, Huang H, Janda K, Edington T: Overexpression of Legumain in tumours is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res 2003; 63: 2957-2964.